Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, has appointed Dr Hazel Jones as chief operating officer.
Following a £10 million Series A financing in October 2022, Dr Jones’s appointment is the next step in the company’s drive to broaden the application of its technology and secure strategic collaboration agreements with pharmaceutical partners.
Dr Jones’s new role involves leading, scaling, and growing the company’s global business operations. She will play an instrumental part in delivering the company’s strategy to commercial and academic partners. Her responsibilities also include long-term strategic planning of logistics and managing alliances with stakeholders.
Dr Jones has held various roles within AstraZeneca, including executive product director of clinical data, and head of business planning and operations in oncology R&D. She was also previously head of combination therapies at Cancer Research UK.
Enhanc3D Genomics has established a genome-wide 3D-sequencing platform (GenLink3D™) that can globally connect enhancer regions and GWAS (genome-wide association study) risk loci to their core target genes.
The GenLink3D platform pipeline is an elegant combination of a proprietary molecular assay with advanced algorithms and machine-learning capability, providing the first genome-wide, high-resolution, mapping of DNA interactions in 3D space.
Enhanc3D Genomics is using this technology to mine the untapped resource of non-coding genome interactions to create an extensive database of candidate therapeutic targets for development with pharmaceutical partners.
“Hazel’s in-depth experience will be invaluable to the next stages of our development, as we seek to establish strategic partnerships to develop our extensive database of candidate therapeutic targets and disease biomarkers,” said CEO Dr Debora Lucarelli.
“With a proven ability to operate autonomously across large-scope projects, combined with a deep understanding of the pharmaceutical development process and a people-centric leadership approach, Hazel will play a central role in driving significant operational change to create maximum value for Enhanc3D Genomics’ stakeholders. I am delighted to welcome Hazel to the team.”
Dr Jones added: “I’m delighted to join the team at such an exciting stage of the company’s development, and to support Enhanc3D’s vision to ultimately improve outcomes for patients through more targeted treatment options.”